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Nuclear Magnetic Resonance 
metabolomics reveals an excretory 
metabolic signature of renal cell 
carcinoma
Márcia S. Monteiro1, António S. Barros2, Joana Pinto2, Márcia Carvalho1,3, Ana S. Pires-Luís4,5, 
Rui Henrique4,5,6, Carmen Jerónimo4,5, Maria de Lourdes Bastos1, Ana M. Gil2,* & 
Paula Guedes de Pinho1,*
RCC usually develops and progresses asymptomatically and, when detected, it is frequently at 
advanced stages and metastatic, entailing a dismal prognosis. Therefore, there is an obvious demand 
for new strategies enabling an earlier diagnosis. The importance of metabolic rearrangements 
for carcinogenesis unlocked a new approach for cancer research, catalyzing the increased use of 
metabolomics. The present study aimed the NMR metabolic profiling of RCC in urine samples from a 
cohort of RCC patients (n = 42) and controls (n = 49). The methodology entailed variable selection of 
the spectra in tandem with multivariate analysis and validation procedures. The retrieval of a disease 
signature was preceded by a systematic evaluation of the impacts of subject age, gender, BMI, and 
smoking habits. The impact of confounders on the urine metabolomics profile of this population 
is residual compared to that of RCC. A 32-metabolite/resonance signature descriptive of RCC was 
unveiled, successfully distinguishing RCC patients from controls in principal component analysis. This 
work demonstrates the value of a systematic metabolomics workflow for the identification of robust 
urinary metabolic biomarkers of RCC. Future studies should entail the validation of the 32-metabolite/
resonance signature found for RCC in independent cohorts, as well as biological validation of the 
putative hypotheses advanced.
Renal cell carcinoma (RCC) is the most common and lethal malignancy of the kidney, accounting for 87% of all 
renal tumors and representing 2–3% of all human cancers1. RCC comprises a range of tumors with distinct histo-
pathological and genetic features, these being traditionally diagnosed by detection of renal masses by ultrasound, 
computed tomography and magnetic resonance imaging1,2. However, many renal masses progress while remain-
ing asymptomatic until the late stages of the disease and, consequently, more than 50% of patients are incidentally 
diagnosed when examined for other clinical purposes and without the suspicion of genitourinary malignancies2,3. 
As a result, up to 20–30% of patients present metastatic disease at the time of diagnosis, being less amenable to be 
cured by surgery and presenting poor prognosis4. Therefore, the development of new diagnostic and follow-up 
methods should certainly have an important impact in RCC clinical management. Possible new strategies may 
rely on the understanding and measurement of metabolic deviations accompanying the disease, preferably using 
non-invasive methods. In this context, metabolomics has been increasingly pursued in relation to cancer, either 
entailing the analysis of tumor tissue (e.g. melanoma5, breast6,7, ovarian8, colorectal9, brain10–12) or of biofluids. 
The use of biofluid metabolomics in cancer research has consistently increased13, minimally invasive samples 
(plasma/serum and urine) having been used to study ovarian14,15, colorectal16, kidney17–19, breast15,20, lung21,22 and 
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liver23–25 cancers, either using Nuclear Magnetic Resonance (NMR) spectroscopy or Mass Spectrometry (MS). 
These studies have unveiled potential disease biomarkers but also significant stumbling blocks regarding the 
impact of systemic effects and confounders e.g. diet, lifestyle, population phenotypes, age, gender26–28.
In the particular case of RCC, metabolomics-based studies have already been successfully applied to paired 
cancer and normal renal tissue29–33, showing its potential to discriminate cancer and normal tissue as well as 
study RCC progression and aggressiveness. A lack of correspondence between altered pathways proposed by 
genomics and metabolomics was observed highlighting that genetics only describes part of the pathophysiologic 
metabolic rearrangements of RCC29. Overall, the studies reported high glutathione levels, high glycolytic and 
pentose phosphate pathway (PPP) activity as well as alterations in the tricarboxylic acid (TCA) cycle and fatty 
acid metabolism29,33. Nevertheless, biofluids such as blood and urine offer the possibility of non-invasive diag-
nosis and monitoring and these have been the subject of recent metabolomics studies. Serum metabolomics has 
unveiled changed levels of glucose, glutamine, pyruvate and lactate34,35 consistent with enhanced glycolytic and 
glutaminolytic activities, showed potential in nephrectomy follow-up34 and patient staging36, and more recently 
produced a possible biomarker cluster of 7 metabolites (alanine, creatine, choline, isoleucine, lactate, leucine, 
valine) for early RCC37. Urine is a particularly suited biofluid concerning kidney cancer, and RCC in particular, 
due to its intimate contact with the urinary system. A number of MS-based metabolomic studies of RCC urine 
have been carried out to illustrate the potential of urine metabolic profiling to differentiate RCC patients from 
controls, two initial reports having considered small sample groups (< 10)17,38 and another MS study addressing 
the impacts of gender, age and geographical origin on urine metabolic profile and discrimination of cancer from 
control samples39. The latter showed that geographic origin was important whereas the impact of gender and age 
was residual. Subsequent MS work, using age-, gender- and ethnic-matched cohorts, identified 13 metabolites 
with statistically different urinary levels between RCC and control samples, and the proposed altered pathways 
included glycolysis, fatty acid metabolism, amino acid (alanine, aspartate, glutamate) metabolism and nicotinate 
and nicotinamide metabolism18. Further work addressed a xenograft mouse model of highly metastatic RCC and 
showed that urine is less reflective of tumoral metabolomic changes compared to tissue or serum19, nevertheless, 
increased urinary levels of some acylcarnitines were found in RCC cases, consistent with previous work40.
Notwithstanding the important developments described above, NMR-based metabolomics studies of RCC 
urine has been relatively underexplored41,42 NMR metabolomics importantly complements MS-based methodol-
ogies since, in spite of its lower sensitivity, it enables a wide range of compound families to be detected, with high 
reproducibility, in a single experiment, thus being particularly suited to untargeted analysis.
This paper reports a NMR profiling study of human urine from a cohort of RCC patients (n = 42) and controls 
(n = 49) building on previous work42 by adding a systematic evaluation of the impacts of subject age, gender, 
body mass index (BMI) and smoking habits, to be later considered when defining a RCC metabolic signature. 
Furthermore, our methodology entailed variable selection of the 1H NMR spectra43, in tandem with multivari-
ate analysis and validation procedures, to more efficiently retrieve meaningful profiles of metabolite variations 
related to confounders and disease. Notably, the thus obtained RCC signature was shown to have classification 
power in unsupervised analysis, for the first time to our knowledge, thus proving its potential in the classification 
of new subjects prior or irrespective of clinical diagnosis. Finally, a preliminary study of clear cell RCC (ccRCC) 
compared to other RCC subtypes, and of different RCC stages was performed.
Results
Figure 1 shows the average 1H NMR spectra of the urine of controls and RCC subjects. A total of 70 metabolites 
have been identified (Table S1), confirming previous reports of urine NMR assignment44–47. Visual comparison 
of the spectra in Fig. 1 suggests apparent decreases in acetate, p-cresol sulfate (p-CS), trimethylamine N-oxide 
(TMAO), hippurate, indoxyl sulfate (IS) and trigonelline, in RCC samples. However, at this stage it is unclear if 
such changes are statistically meaningful and/or reflect the effect of confounders, in addition to disease. Indeed, 
differences in subject age (controls: mean age 67, RCC: mean age 60), gender (controls: 34/15 F/M; RCC: 17/22 
F/M) or lifestyle factors (e.g. smoking habits, dietary habits) may impact on urine composition. The effect of 
these may be decreased using matched cohorts, however, this leads to (1) no applicability of models to subjects 
falling outside the matched range and (2) reduction in sample numbers and, hence, model robustness. In this 
study, we have used spectral variable selection to reduce the impact of random uncontrolled factors (such as 
diet and other lifestyle characteristics) and compared the results obtained using an unmatched cohort and 
an age- and gender-matched sub-cohort (Table 1), while identifying the specific effects of each recognized 
confounder.
Initial PCA of the full spectra of the unmatched cohort (not shown) did not separate controls from RCC 
subjects and PLS-DA provided a model with a very low predictive power (median Q2 0.31) (Fig. 2a, Table S2). 
This result was improved when variable-selected spectra were considered (median Q2 0.59) (Fig. 2b, Table S2), 
reflecting a reduction of random variability effects, as also expressed by a visible improvement in the Q2 distri-
butions plot and ROC curve (Figure S1). When an age- and gender-matched RCC sub-cohort was considered 
(Table 1), the robustness of the PLS-DA model improved marginally (median Q2 0.67) (Fig. 2c, Table S2), thus 
indicating that age and/or gender play a minor role in the present context. Nevertheless, the impact of these vari-
ables on urine profile was quantified in matched sub-cohorts (Figure S2a,b, Table S2) and a corresponding list of 
metabolite variations was obtained (Table 2). Generally, age-related changes were indeed small (effect sizes < 1), 
healthy controls over 60 years excreting slightly higher levels of IS, and lower levels of citrate, cis-aconitate, cre-
atine, creatinine, hypoxanthine and trigonellinamide and some unassigned resonances. Decreased cis-aconitate, 
creatine and cretinine confirmed previous reports48–51 but the remaining characteristics seem to be specific of 
the particular cohort considered here. In addition, healthy males were observed to excrete higher amounts of 
1-methylhistidine, isoleucine, tartrate and unassigned resonances (Un) 3, 4 and 6 (at δ 0.92, 1.15, 6.19 respec-
tively) and less glutamate, 1,6-anhydroglucose and Un 5 (δ 2.05) (Table 2). Interestingly, these variations are, to 
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our knowledge, novel compared to reported gender-related alterations in urine48–51, thus confirming the need 
to establish confounders’ impact for each new (unmatched) cohort under study. Furthermore, since the RCC 
cohort was heterogeneous regarding smoking habits and BMI (Table 1), the impact of these on the metabolic 
profile of patients was also verified (Table S2). When age- and gender-matched sub-cohorts were used, the 
robustness of the PLS-DA model related to smoking habits (SH) was not affected whereas the BMI model was 
improved (median Q2 = 0.57; sensitivity = 96%; specificity = 86% and classification rate = 91%). According to the 
unmatched PLS-DA models, some metabolite variations emerged as possibly related to smoking habits (increased 
trigonelline, hypoxanthine and a number of unassigned resonances, and decreased 3-hydroxy-butyrate (3-HBA), 
4-deoxythreonic acid, allantoin, betaine, guanidinoacetate (GAA) glucose, lactose and scyllo-inositol) and to BMI 
(increased trimethylamine-N-oxide (TMAO) and decreased 3-hydroxy-isovalerate (3-HIVA), citrate and succi-
nate (Table 2). Taking the above confounders into account, both unmatched and matched disease cohorts were 
studied through the corresponding PLS-DA loadings (Fig. 2d, for the unmatched cohort) and spectral integra-
tion, while possible bias due to confounders were identified. Overall, variations in 45 metabolites were identified, 
in addition to changes in several unassigned resonances (Table 3). A total of 32 features exhibited statistical rele-
vance (p < 0.05). These features comprised 20 assigned compounds and were mostly observed in both matched 
and unmatched cohorts. However, changes in GAA, scyllo-inositol and unassigned resonances at δ 4.29, 9.05 
were only revealed in the age- and gender-matched cohort, which suggests such changes may become masked in 
unmatched cohorts. On the other hand, 2-ketoglutarate (2-KG), 4-hydroxyphenylacetate, fumarate, lactate, thre-
onine and trigonellinamide were only observed to change in the unmatched cohort, probably benefiting from the 
higher sample numbers. PLS-DA model computed using only the set of 32 metabolites/resonances was compara-
ble in performance to that obtained with all selected spectral variables (Table S2), thus electing the 32-resonances 
subset as a good descriptor of RCC, when compared to controls. This was confirmed by PCA of the 32-metabolite 
subset (Fig. 3a), which showed very good group separation. Upon removal of bias resonances (those noted with c, 
e, f, g in Table 3), the remaining 23 integrals remarkably retained classification power (median Q2 0.75), compared 
to the 32-resonances model (median Q2 0.68) (Table S2), while PCA improved only very slightly (Fig. 3b), thus 
again demonstrating that age, gender or smoking habits discrepancies do not hinder RCC classification, based on 
the urine profiles of the population under study.
Overall, RCC patients were shown to excrete higher levels of 2-KG, N-methyl-2-pyridone-5-carboxamide 
(2-Py), bile acids (tentative assignment), galactose, hypoxanthine (possible confounder), isoleucine (possible 
confounder), pyruvate, succinate and valine; and lower levels of 4-hydroxyhippurate, 4-hydroxyphenylacetate, 
acetone, GAA, glycine, hippurate, malonate, phenylacetylglutamine (PAG), tartrate and trigonelline (Table 3). 
Figure 1. Average 1H NMR spectra of urine samples from (a) controls and (b) RCC patients. Legend: (1) 
isoleucine, (2) threonine, (3) lactate, (4) alanine, (5) acetate, (6) glutamate, (7) p-cresol sulfate (p-CS), (8) 
acetone, (9) valine, (10) citrate, (11) dimethylamine (DMA), (12) trimethylamine (TMA), (13) dimethylglycine 
(DMG), (14) creatine, (15) trimethylamine-N-oxide (TMAO), (16) 9-methyl-uric acid (tentative assignment), 
(17) methanol, (18) scyllo inositol, (19) glycine, (20) creatine, (21) trigonelline, (22) trigonellinamide, (23) 
unassigned (5.11 ppm), (24) glucose, (25) indoxyl sulfate (IS), (26) phenylacetylglutamine (PAG), (27) 
hippurate, (28) hypoxanthine, (29) formate. Arrows indicate visible spectral alterations. *Excluded regions 
(water and urea).
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These results partially confirm previous suggestions of a 7- metabolite urinary signature of early RCC42, particu-
larly regarding the increases in lactate (not statistically relevant here) and pyruvate (here with p-value 5.43 × 10−7, 
compared to 0.010 in ref. 42) and the decrease in hippurate (here with p-value 4.60 × 10−6, compared to 0.023 in 
ref. 42). Previously observed variations in creatine, alanine, betaine and citrate were either not confirmed in this 
cohort or found to have a confounder contribution (namely, decreased citrate was here related to higher BMI, 
Table 2).
In addition, metabolic differentiation between distinct RCC subtypes and stages was attempted by PLS-DA 
(Table S2). Unfortunately, the low sample numbers for each of the non-ccRCC types only enabled a prelimi-
nary comparison between ccRCC and all other types put together. This revealed small changes (effect sizes < 1) 
in ccRCC cases (higher levels of trimethylamine (TMA), taurine and unassigned doublets at δ 0.75, 0.78 and 
1.25, and lower levels of creatine and trigonellinamide), compared to other types (Table 2). The age-matching 
of ccRCC and other subtypes samples resulted in a slightly improved PLS-DA model (median Q2 = 0.78; sensi-
tivity = 95%; specificity = 93% and classification rate = 91% compared to median Q2 = 0.63; sensitivity = 92%; 
specificity = 90% and classification rate = 91% of the unmatched cohort).
Discussion
The variable selection strategy used here enabled a 32-resonance urinary signature to be identified as charac-
teristic of RCC urinary profile, compared to controls, and putative biochemical pathways are hereby advanced 
relating the metabolite changes observed (Fig. 4). Changes in hippurate levels may arise from sources as varied 
as diet, oxidative stressors and gut microflora and, while hippurate decreases have been reported in a recent 
account of RCC urine metabolomics42 and lung cancer27, some inconsistency is found in other cancer stud-
ies52–54. This indicates the importance of diet/lifestyle parameters in determining the relationship of hippurate 
and cancer. Furthermore, lower levels of excreted hippurate have also been correlated with type-2 diabetes mel-
litus55, obesity55–57 and high blood pressure58, the latter two factors being recognized as risk factors of RCC2,4 
and, indeed, characterizing many of the subjects comprised in our RCC group (n = 9 obese subjects, n = 21 
overweight subjects, n = 27 subjects with high blood pressure). Trigonelline (or N-methylnicotinate) may relate 
to particular dietary products (e.g. coffee) but may also arise from endogenous niacin methylation. Reduced 
excretion of this compound was reported in liver cancer patients59, ovarian cancer patients15, patients with pan-











Controls (total cohort) 49 38–86 66.63 ± 12.85 34 15
 RCC (total cohort) 39 35–79 59.97 ± 11.61 17 22
 Clear-cell (ccRCC) 24 41–79 61.88 ± 11.53 6 18
 Type 1 papillary (pRCC) 6 53–74 60.00 ± 7.56 4 2
 Chromophobe (chRCC) 8 35–71 54.25 ± 14.30 6 2
 Unclassified type 1 60 — 1 —
 Stage I 21 41–79 58.48 ± 11.40 12 9
 Stage II 6 42–78 59.50 ± 11.93 3 3
 Stage III 8 35–76 62.88 ± 14.22 2 6
 Stage IV 4 50–72 62.75 ± 9.22 0 4
 Smokersb 12 35–76 57.67 ± 12.40 4 9
 Non smokers 26 41–79 61.69 ± 10.96 14 12
 BMI ≥ 25 24 35–79 61.33 ± 11.45 11 13
 BMI < 25 12 42–77 59.50 ± 11.77 5 7
Matched sub-cohorts
 Controls vs. RCC, age- and gender-matched
  Controls 28 38–79 61.68 ± 9.96 16 12
  RCC 28 35–79 61.75 ± 10.31 17 12
 Controls ≤ 60 yr vs. Controls > 60 yr, matched for male/female proportion
  Age ≤ 60 20 38–60 53.75 ± 5.33 14 6
  Age > 60 29 61–86 75.52 ± 7.96 20 9
 Control Females vs. Control Males, age-matched
  Female 15 50–86 64.80 ± 12.18 — —
  Male 15 50–85 64.87 ± 12.03 — —
Table 1.  List of urine samples collected for controls and RCC subjects, comprising number of samples, age 
and gender; and, for RCC patients, histopathological cancer type, TNM staging (information not available 
for 1 subject) [2], smoking habits (information not available for 1 subject) and body mass index (BMI, in 
kg.m−2, information not available for 3 subjects). Information on smoking habits and BMI was only available 
for RCC patients. SD: standard deviation. aOne collection per patient. bIncludes smokers (n = 5) and former 
smokers (n = 7).
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(or 1-methylnicotinamide), this change suggests some impairment of nicotinate and nicotinamide metabolism61. 
This may impact on the conversion of nicotinamide to 2-Py, catalyzed by poly(ADP-ribose) polymerase (PARP), 
an enzyme also involved in DNA repair mechanisms, replication, chromatin condensation, cellular response to 
stress and regulation of apoptosis62, thus possibly explaining the increased excretion of 2-Py. Furthermore, altered 
purine metabolism may lead to elevated hypoxanthine levels, as observed in the present study and previously in 
the urine of patients with Non-Hodgkin lymphoma63. An additional note on the above mentioned reduction in 
excreted trigonelline relates to this compound being a byproduct of the conversion of S-adenosylmethionine to 
S-adenosylhomocysteine in the methionine cycle. Indeed, its reduction may also indicate S-adenosylmethionine 
depletion due to its redirection to help replenish reduced glutathione (GSH) levels64, an important cellular anti-
oxidant molecule, believed to be associated with increased production of reactive oxygen species (ROS) in cancer 
cells. The increased level of galactose may be related to its participation in glycolysis. In fact, increased glycolysis 
activity is hereby made clear by the higher levels of excreted pyruvate and subsequent altered levels of several 
tricarboxylic acid (TCA) cycle intermediates, namely 2-KG and succinate. Increased glycolytic flux and altered 
TCA cycle function are well known hallmarks of cancer, affecting not only cellular energetic efficiency but also 
anabolic/biosynthetic efficiency65–67, since intermediates in these pathways are diverted towards the synthesis of 
proteins, nucleic acids, lipids, and cholesterol synthesis66,68–72, and generally aid in the maintenance of cellular 
redox69,71, genetic and epigenetic status69,73 required for cancer cells proliferation. In connection to enhanced gly-
colysis, increased circulating and excreted alanine and lactate levels in RCC have been interpreted as evidence of 
the expected Warburg effect in cancer cells37,42, however, in this cohort we have only observed a small increasing 
tendency for lactate. This suggests that such direct evidence may depend on phenotype and/or become masked by 
inter-subject variability. In addition, the decreased acetone urinary levels found suggest the inhibition of ketogen-
esis, consistent with the reported preferential use of acetyl coenzyme A (acetyl-CoA) by cancer cells as precursor 
of lipids/cholesterol/isoprenoids over the ketogenic pathway74. This hypothesis is consistent with the decreased 
amounts of both acetoacetate and 3-hydroxy-butyrate (3-HBA), also components of ketone bodies, found in 
cancer patients compared to controls (metabolites not discriminant according to their VIP value). Furthermore, 
a ketogenic diet (high fat, low carbohydrate content) has shown to have a protective/therapeutic effect on cancer 
probably because it diminishes the glycolytic flux in cancer cells75,76.
Metabolic deregulation in RCC seems to impact importantly on the levels of glycine (decreased), isoleucine 
(increased) and valine (increased). Glycine is an essential amino acid highly consumed by fast proliferating cancer 
Figure 2. PLS-DA scores scatter plots obtained for the 1H NMR spectra of urine of the unmatched cohort: 
n = 49 controls (○ ) vs. n = 39 RCC patients (● ), (a) without and (b) with variable-selection; (c) age- and 
gender-matched sub-cohort: n = 28 controls (○ ) vs. n = 28 RCC patients (● ), with variable-selection; (d) 
loadings plot corresponding to the model shown in (b). All models were obtained with no. LV = 2. The ellipses 
indicate the 95% confidence limits. The loadings plots are colored according to variable importance to the 
projection (VIP) and some assignments are indicated.
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(±uncertainty) ES (±ESSE) p-value
Metabolite variations in controls > 60 yr (n = 29) vs. controls ≤ 60 yr (n = 20)
 Citrate 2.70 (d) − 19.5 (12.3) − 0.51 (0.58) 4.73 × 10−2(*)
 cis-Aconitatec 3.12 (d) − 17.2 (5.8) − 1.03 (0.61) 2.44 × 10−3
 Creatinec 3.03 (s) − 5.9 (37.1) − 0.04 (0.57) 3.71 × 10−2(*)
 Creatininec 4.06 (s) − 21.4 (6.1) − 1.10 (0.61) 2.37 × 10−4
 Hypoxanthine 8.20 (s), 8.22 (s) − 5.7 (19.9) − 0.07 (0.57) 2.05 × 10−3(*)
 Indoxyl sulfate 7.70 (d) 17.4 (11.7) 0.43 (0.58) 8.42 × 10−3(*)
 Trigonellinamide 9.3 (s) − 37.4 (22.2) − 0.64 (0.58) 9.49 × 10−3
 Un 1 2.07 (s) − 5.5 (3.8) − 0.39 (0.58) 1.38 × 10−2(*)
 Un 2 7.93 (s) − 1.9 (20.9) − 0.02 (0.57) 2.17 × 10−3
 Unassigned region 6.40–6.36 − 19.7 (10.9) − 0.60 (0.58) 2.05 × 10−3(*)
Metabolite variations in control males (n = 15) vs. control females (n = 15)
 1-methylhistidine 7.05 (s) 19.3 (8.1) 0.79 (0.74) 4.04 × 10−2(*)
 1,6-anhydroglucose 5.46 (d) − 20.8 (11.4) − 0.74 (0.74) 3.99 × 10−2(*)
 4-DTAb 1.24 (d) 73.8 (15.3) 1.28 (0.79) 1.66 × 10−3
 Glutamate 2.04 (m) − 7.6 (3.6) − 0.81 (0.74) 3.51 × 10−2(*)
 Isoleucine 0.98 (d) 19.5 (6.0) 1.08 (0.77) 4.19 × 10−3
 Tartrate 4.35 (s) 59.4 (17.1) 0.98 (0.76) 1.86 × 10−2(*)
 Un 3 0.92 (d) 11.2 (4.5) 0.86 (0.75) 2.71 × 10−2(*)
 Un 4 1.15 (d) 2.81 (31.4) 0.03 (0.72) 1.40 × 10−3
 Un 5 2.05 (s) − 10.5 (4.2) − 0.96 (0.76) 1.56 × 10−2(*)
 Un 6 6.19 (s) 336.5 (133.1) 0.34 (0.72) 2.65 × 10−2(*)
 Unassigned region 6.43–6.41 − 25.4 (9.0) − 1.17 (0.77) 9.68 × 10−4
Metabolite variations in smoker + ex-smoker RCC patients (n = 12) vs. non-smokers (n = 26)
 3-HBA 1.20 (d) − 18.2 (15.7) − 0.38 (0.69) 2.32 × 10−2(*)
 4-DTAb 1.24 (d) − 25.2 (12.3) − 0.56 (0.70) 4.16 × 10−2(*)
 Allantoin 5.40 (s) − 25.1 (9.3) − 0.90 (0.71) 6.40 × 10−3
 Betaíne 3.27 (s) − 37.1 (12.5) − 0.89 (0.71) 1.89 × 10−3
 GAA 3.81 (s) − 30.5 (10.6) − 0.98 (0.72) 5.45 × 10−3
 Glucose 5.25 (d) − 46.3 (15.0) − 0.87 (0.71) 1.18 × 10−5
 Hypoxanthine 8.20 (s), 8.22 (s) 48.3 (28.6) 0.62 (0.70) 4.50 × 10−2(*)
 Lactose 5.26 (d) − 20.5 (9.3) − 0.62 (0.70) 4.16 × 10−2(*)
 Scyllo-inositol 3.37 (s) − 26.4 (8.4) − 1.06 (0.72) 1.71 × 10−3
 Trigonelline 9.13 (s) 192.4 (43.2) 1.25 (0.74) 2.16 × 10−3
 Un 7 1.86 (s) 7.8 (13.0) 0.17 (0.69) 3.87 × 10−3
 Un 8 1.88 (d) 19.3 (5.7) 1.30 (0.74) 5.10 × 10−4
 Un 9 2.78 (s) − 22.3 (8.0) − 0.85 (0.71) 2.28 × 10−2(*)
 Un 10 5.35 (s) − 20.5 (9.3) − 0.81 (0.71) 3.87 × 10−3
 Un 11 7.94 (s) 52.2 (14.4) 1.21 (0.74) 1.91 × 10−3
 Un 12 8.66 (d) 57.9 (19.8) 1.09 (0.73) 4.83 × 10−3
 Un 13 8.79 (d) 239.5 (45.0) 1.22 (0.74) 2.16 × 10−3
 Un 14 9.05 (s) 99.64 (46.3) 0.59 (0.70) 2.76 × 10−2(*)
 Unassigned region 8.31–8.24 25.0 (9.0) 0.96 (0.72) 1.79 × 10−2(*)
Metabolite variations in RCC patients with BMI ≥ 25 (n = 24) vs. BM < 25 (n = 12)
 3-HIVA 2.37 (s) − 10.2 (5.0) − 0.74 (0.71) 3.63 × 10−2(*)
 Citrate 2.70 (d) − 26.6 (18.3) − 0.55 (0.70) 4.86 × 10−2(*)
 Succinate 2.42 (s) − 6.2 (5.5) − 0.39 (0.70) 6.20 × 10−14
 TMAO 3.28 (s) 102.3 (21.2) 0.75 (0.71) 1.49 × 10−2(*)
Metabolite variations in RCC patients with ccRCC (n = 24) vs. other subtypes (n = 15)
 Creatine 3.03 (s) − 22.8 (47.4) − 0.16 (0.65) 7.58 × 10−3(*)
 TMA 3.90 (s) 20.7 (7.1) 0.83 (0.67) 1.46 × 10−2(*)
 Trigonellinamide 9.28 (s) − 31.1 (17.9) − 0.76 (0.67) 4.25 × 10−2(*)
 Taurine 3.43 (t) 19.0 (8.4) 0.57 (0.66) 4.94 × 10−2(*)
 Un 15 1.25 (d) 39.6 (9.5) 0.89 (0.67) 1.22 × 10−3
 Un 16 0.75 (d) 16.9 (20.4) 0.27 (0.65) 1.25 × 10−2(*)
 Un 17 0.78 (d) 75.6 (17.1) 0.87 (0.67) 1.25 × 10−2(*)
Table 2.  List of varying metabolites in controls due to different ages (>60 yr and ≤60 yr) and gender 
(top and middle table sections), and in RCC patients (bottom table section) due to different smoking 
habits, BMI (≥25 and <25) and histological subtype (ccRCC and other subtypes) along with % variation, 
effect size (ES), standard errors (SE) and p-value. aChemical shifts of integrated peaks. s: singlet, d: doublet, 
m: multiplet. bTentative assignment. cVariation consistent with previous reports (48–51). 3-HBA: 3-hydroxy-
butyrate; HIVA: 3-hydroxy-isovalerate; 4-DTA: 4-deoxythreonic acid: GAA: guanidinoacetate; TMA: 
trimethylamine; TMAO: trimethylamine-N-oxide. Un i: unassigned spin system i, numbered by order of 
appearance in table. Only signals with p-value < 0.05 are presented. (*)not statistically relevant after BH-FDR 
correction ( 45 ). 
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cells77,78, decreased levels of glycine having also been detected in the urine of prostate cancer patients79. As serine, 
glycine sustains the one-carbon metabolism (folate and methionine cycles) that provides precursors for the bio-
synthesis of several biomolecules80 and the increased uptake of glycine has been suggested to relate to oncogenesis 
and malignancy in several cancer cell lines78. Regarding the branched-chain amino acids valine and isoleucine, 
their urinary levels have also been found increased in human colorectal cancer81 and gastric cancer patients82. 
Both studies have revealed that the levels of these amino acids seem dependent on cancer staging (due to distinct 
extents of proteolysis74) although we have not detected relevant changes in this respect. Other amino acid-related 
changes comprise those affecting PAG and 4-hydroxyphenylacetate, both decreased. PAG is a downstream metab-
olite of phenylacetic acid and glutamine and it has been found elevated in the urine of colorectal cancer patients83 
and decreased in the urine of human bladder cancer84 and lung cancer27. Lower PAG excretion, as that observed 
here, may reflect lower glutamine availability due to enhanced glutaminolysis, a well-known metabolic adaptation 
of cancer cells to sustain TCA cycle activity and amino acids and lipids synthesis85,86. 4-Hydroxyphenylacetate is a 
product of tyrosine metabolism and has also been reported as significantly decreased in the urine of breast cancer 
patients87 and elevated in the plasma of dialysis patients88. It is possible that the decreased excretion of this com-
pound in cancer patients may relate to kidney impairment as a result of cancer progression. Furthermore, GAA 
is an intermediate in the biosynthesis of creatine being synthesized mainly in the kidneys and then converted to 
creatine in the liver89. The combination of arginine and glycine to form GAA is considered the rate-limiting step 
of creatine synthesis, thus, the decreased GAA in urine may be due to an impaired renal function and, its urinary 
excretion has been found decreased in a variety of renal diseases90–92. This is also compatible with the decreased 
creatinine and creatine excretion found in RCC patients compared to controls, which further suggest an impaired 
renal function and subsequently clearance of this compounds. Furthermore, GAA was also found decreased in 
the urine of patients with glioblastoma multiforme93 and bladder cancer94 compared to controls, which may also 
be suggestive of altered muscle energy metabolism as a systemic effect of cancer95. Finally, the tentative assign-
ment of peaks at δ 0.54 and 0.57 as bile acid resonances suggests an impact of RCC on the endogenous cholesterol 
metabolism. Bile acids are considered in general as markers of liver injury96 and have indeed been found elevated 
in both serum and urine of patients with hepatocellular carcinoma97. However, the particular relationship of these 
compounds with RCC remains unclear, at this stage.
Conclusions
The results presented here firstly confirm the importance of evaluating the effects of age and gender (as well as of 
relevant lifestyle parameters) on urine composition, as part of an initial phenotypic characterization of the spe-
cific cohort under study. Based on the evaluation of the impacts of age, gender, smoking habits and BMI on uri-
nary profile, we concluded that the impact of these potential confounders is residual, in this population, in terms 
of RCC classification, although it determines the exact nature of the retrieved disease signature. Hence, the use of 
unmatched cohorts was found not to hinder successful RCC classification within the present cohort. The results 
also show that RCC may be successfully described by changes in a total of 32 compounds/resonances (or 23 
resonances, if possible biased variables are excluded). Putative interpretation of the identified metabolites chang-
ing in RCC, compared to controls, identified possible unspecific effects involving hippurate, trigonelline and 
trigonellinamide, thus reflecting the importance of diet and gut microflora, as well as nicotinate and nicotinamide 
metabolism and anti-oxidative mechanisms as less specific systemic effects of cancer. Additional metabolic effects 
accompanying RCC, probably of a more specific nature, include disturbances in galactose metabolism, probably 
in association with the expected enhanced glycolysis activity34,35. The latter was seen to be accompanied by adap-
tations of the TCA cycle, ketogenesis, selected amino acid metabolism (glycine, isoleucine and valine), creatine 
and creatinine metabolism and, possibly, endogenous cholesterol metabolism. These biochemical hypotheses will 
require future validation through complementary biological measurements, a process which would also benefit 
from further efforts in the assignment of many important still unassigned NMR resonances. In addition, natural 
follow-ups of these findings comprise external validation of the 32-resonance RCC signature found here, using 
external independent sets of subjects of the same geographical origin as the training cohort used here. In fact, the 
possible dependence of the metabolic signature on geographical origin and, in general, on population phenotype 
needs to be investigated, as it may explain discrepancies between independent studies and, most importantly, 
unveil the need to define distinct metabolic biomarkers for different populations.
Methods
Subjects. The cohort enrolled in this study comprised thirty-nine patients diagnosed with primary RCC (17 
females and 22 males; age range 35–79, average age 60) and forty-nine healthy control (cancer-free) subjects (34 
females and 15 males; age range 38–86, average age 67) (Table 1). These groups did not include diabetic patients 
or subjects suffering from other acute conditions. Table 1 also shows the histopathological types of the RCC tum-
ors diagnosed, TNM staging2, and information on subject age, gender, and, in the case of RCC patients, smoking 
habits and BMI (information not available for control subjects). All subjects signed informed consents and the 
study was approved by the Ethics Committee of the Portuguese Oncology Institute-Porto (CES76/2012). All the 
experiments were performed in accordance with the relevant approved guidelines and regulations. The patients 
provided urine samples preoperatively, none having undergone radiation or chemotherapy treatment. Each sub-
ject, either patient or healthy volunteer, provided a sample of first void urine sample (after overnight fasting) in a 
sterile cup. All samples were then centrifuged (4000 rpm, 20 min, 4 °C) and split into several aliquots transferred 
into cryovials and stored at − 80 °C until NMR analysis.
Sample preparation. Prior to NMR analysis, urine samples were thawed (room temperature) and cen-
trifuged (8000 rpm, 5 min, 4 °C) to remove cells and other precipitated material. Then, 60 μ L of buffer solution 
(1.5 M phosphate buffer pH 7.0 in D2O) containing 0.1% of 3-trimethylsilyl-propionate (TSP), used as chemical 
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(relatively to controls) ES (±SE) p-value
1-methylhistidineb 7.05 (s) − 5.2 (5.9) − 0.20 (0.42)
2-KGb 2.45 (t) 74.3 (6.1) 2.08 (0.52) 1.47 × 10−12
2-Py 8.33 (s) 32.3 (12.2) 0.54 (0.43) 8.15 × 10−3
3-methylhistidineb 8.11 (s) 4.9 (13.3) 0.08 (0.42)
3-HIBAb 1.36 (s) 4.7 (5.6) 0.18 (0.42)
3-HIVA 2.37 (s) 3.0 (5.1) 0.13 (0.42)
4-DTA 1.24 (d) − 19.9 (11.0) − 0.41 (0.43)
4-hydroxyhippurate 7.76 (d) − 51.3 (11.3) − 1.17 (0.45) 2.95 × 10−9
4-hydroxyphenylacetateb 6.88 (d) − 13.9 (6.6) − 0.47 (0.32) 5.09 × 10−3
Acetate 1.93 (s) − 63.2 (37.2) − 0.45 (0.43)
Acetone 2.24 (s) − 6.6 (7.7) − 0.21 (0.42) 1.54 × 10−4
Allantoinc 5.40 (s) 6.4 (7.2) 0.19 (0.42)
Ascorbate 4.53 (d) − 14.4 (7.0) − 0.47 (0.43)
Bile acid† 0.54 (s) 75.5 (13.7) 0.92 (0.44) 5.51 × 10−6
Bile acid† 0.57 (s) 101.0 (15.2) 1.04 (0.45) 1.61 × 10−7
DMA 2.73 (s) − 8.1 (8.8) − 0.19 (0.42)
Citrated,e 2.70 (s) − 9.1 (24.0) 0.19 (0.53)
cis-aconitate 3.12 (d) − 5.8 (4.0) − 0.31 (0.42)
Creatined 3.03 (s) − 4.1 (36.9) − 0.03 (0.52)
Creatinined 4.06 (s) − 0.5 (6.2) − 0.02 (0.52)
Formated 8.45 (s) − 9.1 (24.0) − 0.11 (0.52)
Fumarateb 6.53 (s) 16.7 (15.1) 0.24 (0.42)
Furoylglycine 7.68 (d) 5.8 (3.6) 0.33 (0.42)
GAAd 3.81 (s) − 16.7 (9.2) − 0.53 (0.53) 3.05 × 10−2(*)
Galactose 5.28 (d) 55.6 (20.7) 0.50 (0.43) 9.75 × 10−6
Glutamate 2.04 (m) 2.8 (2.5) 0.25 (0.42)
Glutamine 2.44 (m) 8.7 (5.1) 0.36 (0.42)
Glycine 3.57 (s) − 21.7 (7.1) − 0.71 (0.43) 1.68 × 10−3
Hippurate 7.56 (t) − 42.2 (12.9) − 0.87 (0.44) 4.60 × 10−6
Hypoxanthinef 8.20 (s), 8.22 (s) 23.4 (16.0) 0.29 (0.42) 5.64 × 10−3
Indoxyl sulfate 7.70 (d) 4.7 (9.5) 0.11 (0.42)
Isoleucineg 0.98 (d) 13.5 (4.9) 0.56 (0.43) 4.58 × 10−3
Lactateb 1.34 (d) 1.6 (5.8) 0.06 (0.42)
Malonate 3.11 (s) − 17.6 (15.0) − 0.27 (0.42) 4.79 × 10−2(*)
PAG 7.43 (m) − 11.0 (11.9) − 0.22 (0.42) 2.28 × 10−2(*)
Pyruvate 2.41 (s) 32.3 (5.5) 1.15 (0.45) 5.43 × 10−7
Scyllo inositold 3.37 (s) − 1.3 (6.7) − 0.05 (0.52)
Succinate 2.42 (s) 16.2 (3.4) 1.00 (0.45) 3.02 × 10−5
Tartrate 4.35 (s) − 45.8 (10.8) − 1.10 (0.45) 1.26 × 10−8
Taurine 3.43 (t) − 7.5 (7.1) − 0.23 (0.42)
Threonineb 1.33 (d) − 4.0 (9.4) − 0.10 (0.42)
Trigonellinamideb 9.28 (s) − 0.3 (14.0) − 0.01 (0.42)
Trigonellinec 9.13 (s) − 28.8 (16.7) − 0.43 (0.45) 5.22 × 10−4
TMA 3.90 (s) − 14.0 (8.2) − 0.36 (0.42)
Valine 1.05 (d) 14.4 (4.1) 0.73 (0.43) 2.98 × 10−3
Metabolite variations in unassigned compounds, ordered by ppm (ppm, multiplicity)
 Un 16 0.75, d 10.6 (13.0) 0.17 (0.42)
 Un 17 0.78, d − 16.0 (15.5) − 0.23 (0.42)
 Un 18 0.83, s 10.2 (7.6) 0.29 (0.42)
 Un 7c 1.86, s − 5.0 (7.7) − 0.15 (0.42) 1.27 × 10−2
 Un 1c 1.88, d − 5.8 (3.5) − 0.36 (0.42)
 Un 20 1.96, s − 8.1 (6.6) − 0.25 (0.42)
 Un 5 2.05, s 14.4 (3.4) 0.85 (0.44) 4.77 × 10−6
 Un 1f 2.07, s 11.8 (3.0) 0.80 (0.44) 4.00 × 10−5
 Un 21d 2.17, d − 3.0 (26.9) − 0.03 (0.52)
Continued
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shift reference, were added to 540 μ L of each urine sample. Fine pH readjustment to 7.00 ± 0.02 was carried out 
with 4 M solutions of KOD or DCl. The resultant mixture was centrifuged (8000 rpm, 5 min, 4 °C) and 550 μ L were 
transferred to a 5 mm NMR tube.
NMR measurements. NMR spectra were acquired at 300 K on a Bruker Avance DRX-500 spectrometer 
operating at 500.13 MHz for proton and equipped with a 5 mm TXI probe. For each sample, a standard 1D 1H 
NMR spectrum was acquired, using a ‘noesypr1d’ (Bruker library) pulse sequence with water suppression during 






(relatively to controls) ES (±SE) p-value
 Un 22 2.38, s − 18.6 (7.2) − 0.55 (0.43) 1.45 × 10−3
 Un 23d 2.39, s 9.1 (4.8) 0.49 (0.53)
 Un 24 2.50, s 13.5 (3.5) 0.80 (0.44) 3.29 × 10−4
 Un 25 2.76, s 32.8 (4.1) 1.61 (0.48) 5.99 × 10−11
 Un 9c 2.78, s 11.3 (6.8) 0.34 (0.42) 4.56 × 10−2(*)
 Un 26d 4.29, m 10.3 (4.4) 0.60 (0.54) 3.19 × 10−2
 Un 10c 5.35, s 22.9 (9.7) 0.49 (0.43)
 Un 6g 6.19, s 69.5 (13.2) 0.91 (0.44) 1.31 × 10−6
 Un 27 6.49, d 157.7 (30.6) 0.73 (0.43) 2.52 × 10−2(*)
 Un 12 8.66, d 6.7 (10.1) 0.15 (0.42)
 Un 28 8.68, s 13.9 (16.6) 0.18 (0.42)
 Un 29 8.70, d − 142.1 (371.2) − 0.25 (0.42)
 Un 13 8.79, d 77.8 (28.5) 0.48 (0.43)
 Un 14d,c 9.05, s − 33.8 (29.9) − 0.36 (0.53) 3.67 × 10−2(*)
Unassigned spectral regions
 0.87–0.84 − 1.7 (5.8) − 0.06 (0.42)
 6.40–6.36f 16.1 (12.7) 0.27 (0.42)
 6.43–6.41g − 14.1 (9.6) − 0.34 (0.42) 1.25 × 10−2
 6.46–6.44 26.4 (9.8) 0.53 (0.43)
 8.31–8.24d − 1.2 (12.4) − 0.03 (0.52)
T ab le 3.  List of varying metabolites in the RCC groups, compared to controls, along with % variation 
(±% uncertainty), effect size (ES), standard error (SE) and p-value. aChemical shifts of integrated peaks; 
s: singlet, d: doublet, t: triplet; m: multiplet. bVariation only detected in the unmatched cohort but unrelated 
to age, gender, smoking habits or BMI. cMay have contribution from different smoking habits. dVariation 
only detected in the age- and gender-matched model. eMay have contribution from BMI. fMay have 
contribution from higher mean age of controls. gMay have contribution from higher proportion of females 
in controls. 2-KG: 2-ketoglutarate; 2-Py: N-methyl-2-pyridone-5-carboxamide; DMA: dimethylamine; PAG: 
phenylacetylglutamine. Un i: unassigned compound i, numbering follows that indicated in Table 2. Only  
p-values < 0.05 are indicated. (*)not statistically relevant after BH-FDR correction (45). †Tentative assignment.
Figure 3. PCA scores scatter plots obtained for the NMR spectra of the urine of the unmatched cohort: n = 49 
controls (○ ) vs. n = 39 RCC patients (● ), (a) with the 32-resonance subset and (b) with the 23-metabolite 
signature, i.e. with bias resonances removed. All models were obtained with 2 principal components and the 
ellipses indicate the 95% confidence limits.
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(SW) 10000 Hz, 64 k data points and 128 transients. All free induction decays (FID) were multiplied by a 0.3 Hz 
line-broadening factor prior to Fourier Transformation (FT). Spectra were manually phased, baseline corrected, 
and internally referenced to TSP at δ 0.00 ppm (TopSpin 3.2). 2D homonuclear and heteronuclear spectra were 
recorded for selected samples to aid spectral assignment. Specifically, 1H-1H NMR total correlation spectroscopy 
(TOCSY) spectra (‘dipsi2phpr’ pulse sequence) were acquired in phase sensitive mode using time proportional 
phase incrementation (TPPI) and the MLEV17 pulse sequence for spin locking, with acquisition parameters: 
4096 data points in dimension 1 (F1) and 256 data points in dimension 2 (F2), 40 scans and SW 8012.82 Hz in 
both dimensions, relaxation delay 1.5 s, mixing time of MLEV spin lock 80 ms. 1H-13C phase sensitive (echo/
antiecho) heteronuclear single quantum correlation (HSQC) experiments were recorded with inverse detection 
and 13C decoupling (‘hsqcetgp’ pulse sequence), a total of 2048 data points in both dimensions, 40 scans and SW 
8012.82 Hz (F1) and 20831.98 Hz (F2). A relaxation delay of 1.5 s was employed and a refocusing delay equal 
to 1/4 1Jc-H (1.72 ms) was used. For both TOCSY and HSQC spectra, zero-filling to 1024 data points and for-
ward linear prediction were used in f1 and multiplication by a shifted sinebell-squared apodization function was 
applied in both dimensions prior to FT and phasing. 1D and 2D spectra were compared to reference spectra in 
the BBIORFCODE-2-0-0 database (Bruker Biospin, Rheinstetten, Germany), as well as other existing databases98 
and literature reports44,46,47. Statistical Total Correlation Spectroscopy (STOCSY) was also used to aid peak assign-
ment, based on the fact that the method identifies correlated peak intensities arising from the same molecule, as 
well as from biochemically related molecules99.
Multivariate Statistical Analysis. The spectral region between 9.40–0.50 ppm was considered for mul-
tivariate analysis, after exclusion of residual water (5.48–6.16 ppm) and urea (4.62–5.06 ppm) spectral regions 
(AMIX software Bruker GmbH). Spectra were aligned using recursive segment-wise peak alignment100, 
Figure 4. Schematic representation of possibly affected metabolic pathways in RCC. Metabolites found 
significantly increased and decreased in the urine of RCC patients are presented in green and red, respectively. 
Metabolic steps hypothesized as up-regulated are presented by bold arrows and those that seem compromised 
as dashed arrows. 2-HBA: 2-hydroxy-butyrate acid;2-KG: 2-ketoglutarate; 2-Py: N-methyl-2-pyridone-5-
carboxamide; AMP:adenosine monophosphate; GAA: guanidinoacetate; GMP: deoxy-guanosine; GSH: 
gluthatione; PAG:phenylacetylglutamine.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:37275 | DOI: 10.1038/srep37275
normalized by probabilistic quotient normalization (PQN)101 (Matlab 7.12.0, The MathWorks, Inc) and scaled to 
unit variance (UV) (SIMCA-P 11.5, Umetrics, Umea, Sweden). Principal component analysis (PCA) and partial 
least-squares discriminant analysis (PLS-DA) were applied to the NMR spectra (SIMCA-P 11.5, Umetrics, Umea, 
Sweden). PLS-DA model robustness was assessed by Monte Carlo Cross Validation (MCCV) using 500 iterations. 
For each of the 500 randomly generated classification models, Q2 values (predictive power), number of Latent 
Variables (LV), and confusion matrices of original and randomly permuted classes were retrieved. Sensitivity 
(sens), specificity (spec) and classification rates (CR) were computed and the predictive power of each model was 
further assessed using a Receiver Operating Characteristic (ROC) map, a function of the true positive rate (TPR 
or sensitivity) and false positive rate (FPR or 1-specificity). PLS-DA models were considered robust when min-
imal overlap of the original (alternative hypothesis) and randomly permuted (null hypothesis) Q2 distributions 
were obtained. For variable selection studies, spectral variables were selected through the intersection of three 
conditions: VIP > 1 and VIP/VIPcvSE > 1 and |b/bcvSE| > 143. After variable selection, PLS-DA was reapplied and 
resubmitted to MCCV. For all models computed, the relevant peaks/metabolites contributing to class discrim-
ination were integrated in the original spectra (AMIX software Bruker GmbH) and PQN normalized (Matlab 
7.12.0, The MathWorks, Inc). All integrals were compared through the two-samples Student t-test or the nonpar-
ametric analogue Wilcoxon rank sum test (statistical relevance considered for p < 0.05, confidence level 95%). 
Additionally, the Benjamini-Hochberg false discovery rate (BH-FDR) correction method102 was used to adjust 
p-values for multiple comparisons (corrected p-value = p-value*(n/(n-2)), where n = number of metabolites/res-
onances tested) and a significance cut-off equal to 0.05 considered. Furthermore, effect size values were calculated 
following the definition given in Berben et al.103.
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